Disclosed is a use of an isolated antibody or antibody fragment specific for IL17C for the manufacture of a medicament for the treatment of an inflammatory disorder, wherein the inflammatory disorder is pulmonary inflammation, psoriasis, rheumatoid arthritis and/or COPD (chronic obstructive pulmonary disease), wherein IL17C consists of amino acids of the sequence as defined in the specification, and wherein the antibody blocks the binding of IL17C to IL17RE.